High materiality7/10
Goldman Sachs Starts Adeptus Biotechnologies Corp. (ADPT) at Buy
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Goldman Sachs initiates ADPT with a Buy rating and a $35 target; current price around $28.51, signaling near-term upside.
- Target: $35
- Posted price: $28.51
- Firm: Goldman Sachs
- Analyst: Evie Koslosky
- Change: +0.88
Key facts
- 01
Target: $35
- 02
Posted price: $28.51
- 03
Analyst firm: Goldman Sachs
- 04
Analyst: Evie Koslosky
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.